Wave Life Sciences, Inc.

For the period ended Sep 30, 2026. Filed Oct 27, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Oct 27, 2026

WVE$3.41-2.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Consolidated Balance Sheets

	September 30, 2026	December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$197,315	$602,068
Marketable securities	233,434	—
Accounts receivable	12,000	1,276
Prepaid expenses	11,556	8,395
Other current assets	4,325	3,075
Total current assets	458,630	614,814
Long-term assets:
Property and equipment, net of accumulated depreciation of $51,391 and $49,522 as of September 30, 2026 and December 31, 2025, respectively	6,239	7,405
Long-term marketable securities	263	—
Operating lease right-of-use assets	38,088	12,458
Restricted cash	3,815	3,806
Other assets	895	16
Total long-term assets	49,300	23,685
Total assets	$507,930	$638,499
Liabilities, Series A preferred stock, and stockholders’ equity
Current liabilities:
Accounts payable	$19,295	$15,700
Accrued expenses and other current liabilities	21,979	26,564
Current portion of deferred revenue	9,111	44,440
Current portion of operating lease liability	4,375	8,361
Total current liabilities	54,760	95,065
Long-term liabilities:
Deferred revenue, net of current portion	12,338	7,798
Operating lease liability, net of current portion	38,896	9,405
Total long-term liabilities	51,234	17,203
Total liabilities	$105,994	$112,268
Series A preferred stock, no par value; nil and 3,901,348 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively	$—	$7,874
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 30,000,000 shares authorized; nil shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively	$—	$—
Common stock, $0.001 par value per share; 500,000,000 shares authorized; 197,213,583 and nil shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively	197	1,616,478
Additional paid-in capital	1,885,894	228,365
Accumulated other comprehensive loss	(565)	(250)
Accumulated deficit	(1,483,590)	(1,326,236)
Total stockholders’ equity	$401,936	$518,357
Total liabilities, Series A preferred stock, and stockholders’ equity	$507,930	$638,499

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.